Story

DiaSorin Downgraded to 'Sell' by UBS on Rising Roche Competition

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20262 min read
DiaSorin Downgraded to 'Sell' by UBS on Rising Roche Competition
Text size
Background

UBS downgraded DiaSorin SpA to "Sell" from "Neutral" and slashed its price target to €55 from €66, flagging that growth expectations for the Italian biotech firm have "outrun competitive reality." The bank's analysts stated that mounting competition, particularly from diagnostics giant Roche, challenges the outlook for DiaSorin's key business segments.

In response to the downgrade, shares of DiaSorin fell 3.2% in morning trade, according to the source. The new price target from UBS implies a potential downside of approximately 25% from the company's previous closing price of €76.58.

Competitive Pressures Mount

The core of the bank's thesis rests on a "material step-up in competition" from Roche. UBS highlighted several specific threats:

  • Latent Tuberculosis Testing: Roche launched a competing immunoassay in Europe in June, with a U.S. launch anticipated. This directly challenges DiaSorin's established Quantiferon product.
  • Lyme Disease Testing: Roche is expected to launch its own Lyme immunoassays starting in 2027, entering another key market for DiaSorin.
  • China Headwinds: UBS increased its price-erosion assumption for a pending test-fee unification policy in China to roughly 45% from 35%, which it estimates could reduce DiaSorin's group growth by about one percentage point in 2027.

Analysts at UBS believe Roche's broader menu of tests could reduce the incentive for laboratories to install DiaSorin's connected systems, posing a risk to future instrument placements.

Sample IUX Markets – In-articleAd

Revised Financial Outlook

UBS now forecasts that DiaSorin's growth will lag both management guidance and market consensus. For the Immunodiagnostics division, which constitutes about 70% of revenue, the bank models a 4% compound annual growth rate (CAGR) through 2030, below the consensus of 5.5%.

In Molecular diagnostics, UBS projects an 8% CAGR, significantly lower than the low-teens growth expected by consensus. The bank noted it was skeptical that DiaSorin's new Liaison Nes platform could capture the 50% of incremental market demand needed to meet guidance, instead modeling a more conservative 15% share.

As a result, UBS's estimates for DiaSorin's adjusted EBIT are now 4% to 6% below consensus for 2026 and subsequent years. The bank also cited the stock's valuation, noting it trades at a 15% P/E premium to its peer Biomerieux, a reversal of its historical discount, which adds to its cautious stance.

Read next

More on Stocks
Back to latest news

LATEST